Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: STNM-01

Latest Information Update: 08 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stelic Institute & Co
  • Developer Sameshima Hospital; Stelic Institute & Co
  • Class Anti-inflammatories; Antifibrotics; Antiulcers
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Phase I Crohn's disease

Most Recent Events

  • 08 Dec 2017 3288368 - updaedd KDM, TT sec, PD sec and HE (assumed PD data, not very sure)
  • 09 Nov 2017 Stelic Institute completes a phase I clinical trial for Ulcerative colitis and Crohn's disease (Treatment-experienced) in Japan (Submucosal) (UMIN000020900; 9226074)
  • 28 Oct 2017 Efficacy and pharmacodynamic data from a phase IIa trial in Ulcerative colitis presented at the 25th United European Gastroenterology Week (UEGW-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top